Additionally, HDAC inhibition increased the synthetic lethality of the PARP inhibitor veliparib/ABT-888 in prostate cancer cells by inhibiting HR DNA repair signaling [45]. This evidence concerns the gene HDAC9 and prostate carcinoma.